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Essentials
• Triple-positivity is associated with a high risk for a first
thrombotic event and recurrence.
• Identification of triple-positives is dependent on the
solid phase assay used.
• In triple-positivity, IgM only adds value in thrombotic
risk stratification together with IgG.
• Thrombotic risk in triple-positive patients with IgM
only, depends on the platform.
Abstract. Background: The antiphospholipid syndrome
(APS) is characterized by thrombosis and/or pregnancy
morbidity with the persistent presence of antiphospholipid
antibodies (aPL). Triple-positivity (i.e. positivity for lupus
anticoagulant [LAC], anti-cardiolipin [aCL] and anti-b2g-
lycoprotein I [ab2GPI] antibodies) is associated with a high
thrombotic risk. Objectives: We investigated the variability
in triple-positivity detection by measuring the same samples
with four commercially available solid phase assays. In
addition, the added clinical value of aPL in LAC-positive
patients was investigated, as well as the association of IgM
triple-positivity and thrombosis. Patients/Methods: We
included 851 patients from seven European medical centers.
Anti-CL and ab2GPI IgG/IgM antibodies were determined
by four platforms: BioPlex2200, ImmunoCapEliA, ACL
AcuStar and QUANTA Lite ELISA. Results: Triple-
positivity detection by solid phase assays varied, ranging
from 89 up to 118 in thrombotic APS patients (n = 258), of
which 86 were detected independent of the platform. Lupus
anticoagulant positivity resulted in an odds ratio (OR) for
thrombosis of 3.4; triple-positivity (irrespective of the iso-
type) increased the OR from 4.3 up to 5.2, dependent on
the platform. Triple-positivity solely for the IgM isotype
did not increase the OR for thrombosis compared with
LAC positivity. The highest OR for thrombosis was
reached for positivity for IgG and IgM ab2GPI and aCL
(8.6 up to 28.9). Conclusions: Triple-positivity proved to
be highly associated with thrombosis, but identification is
assay dependent. Within triple-positivity, IgM antibodies
only have an added clinical value in patients positive for
IgG antibodies.
Keywords: antiphospholipid antibodies; immunoassays;
immunoglobulin isotypes; risk assessment; thrombosis.
Introduction
The antiphospholipid syndrome (APS) is characterized by
thrombosis and/or pregnancy morbidity with the persis-
tent presence of antiphospholipid antibodies (aPL) [1].
Laboratory criteria include aPL detection by phospho-
lipid-dependent coagulation tests referred to as lupus
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anticoagulant (LAC) or by quantitative solid phase assays
measuring anti-b2glycoprotein I (ab2GPI) and anti-cardi-
olipin (aCL) IgG/IgM antibodies [1]. Given the high fre-
quency of thrombosis irrespective of the syndrome,
laboratory tests are of utmost importance for the classifi-
cation of APS. Detection of aPL by solid phase assays is
associated with high inter-laboratory and inter-method
variation [2,3]. Reports from external quality control pro-
grams illustrate that commercially available aPL assays
produce variable results [4–6].
In order to improve the identification of patients at
risk, it was suggested that APS patients should be evalu-
ated according to their aPL profile [1,7]. Combined
positivity for LAC, aCL and ab2GPI antibodies (i.e.
triple-positivity) has been shown to be associated with a
high risk of both a first thrombotic event and recurrence
[8–10]. In the NOH-APS study, a large observational
study, triple-positivity was a predictor for thrombosis in
purely obstetric APS patients [11]. However, computed
risks for thrombosis of LAC positivity and triple-positivity
were globally concordant, with the exception of pulmonary
embolism [11]. Despite the high correlation of triple-
positives with thrombosis, the predictive value is argued to
originate from LAC positivity [12]. Recently, the detection
of triple-positivity (i.e. positivity for LAC, aCL and
ab2GPI antibodies) was suggested to be method and plat-
form independent [13].
Looking at the isotype of aPL, both IgG and IgM anti-
bodies directed against cardiolipin and b2GPI are included
in the Sydney criteria [1]. However, the clinical value of
IgM antibodies in thrombotic APS is debated [14]. To date,
the thrombotic association of IgM antibodies in aPL pro-
files such as triple-positivity is not known. In this study we
included 851 patients from seven European medical cen-
ters. Four solid-phase assay platforms were selected based
on frequency of use and the willingness of manufacturers
to provide their assays. The samples were tested with all
assays at one location by a single technician.
In a retrospective multicenter study we aimed to inves-
tigate the variability in triple-positivity detection between
different aPL detection platforms and the impact of the
platform on the association of triple-positivity with
thrombosis. In addition, we aimed to assess the added
value of aPL detection in LAC-positive patients and the
impact of the isotype with respect to the association with
thrombosis.
Materials and methods
Study population
We included 851 patients from seven European medical
centers. Classification of APS was based on the Sydney
criteria [1]. Patients were classified by the local centers,
resulting in 258 thrombotic APS patients (APS
thrombosis), 204 patients with a history of thrombosis
and negative for laboratory criteria of APS (non-APS
thrombosis), 196 patients with an autoimmune disease
other than APS, such as systemic lupus erythematosus
(52%) and systemic sclerosis (27%), without thrombotic
complications (AID controls), and 193 controls that were
referred for aPL testing for other reasons than the clinical
criteria of APS, including subfertility and prolonged acti-
vated partial thromboplastin time (controls). Patients
were enrolled within a time-span of 1 year, with patient
samples stored for less than 5 years. Thrombosis was
objectively confirmed according to the Sydney criteria [1].
The majority of thrombotic APS patients received antico-
agulant therapy, including vitamin K antagonists (VKAs)
(46%), low-molecular-weight heparins (LMWHs) (5%)
and direct oral anticoagulants (DOACs) (4%). Twenty-
seven patients (10%) received antiplatelet therapy and
only 2% of patients with thrombotic APS received both
anticoagulant and antiplatelet therapy. Details on antico-
agulant and antiplatelet therapy of the remaining 84
patients are not available. Women classified with obstetri-
cal APS were excluded. The study was approved by the
local ethical committees. Lupus anticoagulant positivity
was determined by the local center, according to the
ISTH-SSC (International Society of Thrombosis and
Haemostasis-Scientific Standardisation Subcommittee)
guideline [15]
Solid phase assays
Commercially available solid phase assays (Table S1) were
selected based on frequently used assays in the external
quality control program of the ECAT (External quality
Control of diagnostic Assays and Tests, Leiden, the
Netherlands) and the willingness of manufacturers to col-
laborate. Anti-CL IgG, aCL IgM, ab2GPI IgG and
ab2GPI IgM antiphospholipid antibodies were detected by
BioPlex2200 (Bio-Rad, Bio-Rad Laboratories, Hercules,
USA), ImmunoCapEliA (Thermo Fisher Scientific/
Phadia, Uppsala, Sweden), ACL AcuStar (Werfen/Instru-
mentation Laboratories, Bedford, MA, USA) and
QUANTA Lite ELISA (Inova Diagnostics, San Diego,
CA, USA) in the Ghent University Hospital (Ghent, Bel-
gium). Reagents used for the detection of aCL and ab2GPI
IgG/IgM antibodies were measured with their correspond-
ing instruments according to the manufacturer’s instruc-
tions. All four methods were performed in parallel runs of
40 samples. Antiphospholipid antibody titers were
expressed in arbitrary units (GPL, MPL, U mL1, SGU or
SMU). All samples were measured by the same technician
and values below the calculated limit of detection (LOD)
were replaced by the LOD. Manufacturer’s recommended
cut-off values were used upon confirmation in 20 healthy
volunteers, in accordance with the ISTH-SSC guideline
[16].
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Statistics
Significance of differences between aPL titers was deter-
mined with the Mann–Whitney U-test. Diagnostic efficacy
was assessed within the total population by sensitivity,
specificity and odds ratios (ORs) using the Statistical
Package for Social Sciences (SPSS 23.0; SPSS, Chicago,
IL, USA) and MedCalc Statistical Software version
17.7.2 (MedCalc Software bvba, Ostend, Belgium). Statis-
tical significance was set at P value less than 0.05.
Results
We measured aCL IgG/IgM and ab2GPI IgG/IgM aPL
in 833 individuals with a mean age of 46 years ranging
from 16 to 87 years old (Table 1) with four commercially
available assays (Table S1). In our study population,
venous thrombosis (VT) was more common than arterial
thrombosis (AT), both in the APS and control group. In
addition, primary APS (PAPS) was more prevalent than
APS secondary to an underlying connective tissue disor-
der (SAPS).
From the 851 samples tested, 274 were LAC positive,
and for these triple-positivity ranged from 106 (39%) up
to 146 (53%) detected by QUANTA Lite ELISA and
BioPlex2200, respectively (Table 2). In patients diag-
nosed with thrombotic APS (n = 258), 202 were positive
for LAC. From these 202 LAC-positive samples 118, 101,
111 and 89 were defined as triple-positive (positivity for
LAC, aCL IgG or IgM and ab2GPI IgG or IgM),
detected with the solid phase assays: BioPlex 2200,
ImmunoCap EliA, ACL AcuStar and QUANTA Lite
ELISA, respectively (Table 2). By a comparison of two
proportions, triple-positivity detection was found to be
statistically different between BioPlex 2200 and
QUANTA Lite ELISA (P = 0.0122). Other combina-
tions proved not to be statistically different, although the
comparison of ACL AcuStar and QUANTA Lite
ELISA almost reached statistical significance
(P = 0.0586). Of the LAC-positive patients not defined as
triple-positive, the majority was isolated LAC positive
(Table S2).
Agreement of triple-positivity detection by solid phase
assays was assessed by a 2 9 2 contingency table within
the total population (Table 3). Discrepancies varied
between 14 (BioPlex2200 vs. ACL AcuStar) and 48
(BioPlex 2200 vs. QUANTA Lite ELISA) individuals.
In patients diagnosed with thrombotic APS (n = 258) 118
triple-positives were detected by BioPlex 2200, of which
86 patients were defined as triple-positive, independent of
the solid phase assay used (Table 4). On the other hand,
32 patients were defined as triple-positive by BioPlex
2200 but negative by all the other tested solid phase
assays (Table 4). However, the majority of patients with
Table 1 Demographic and clinical characteristics of the study population
Patients
(n) Female
Age, year,
mean (range)
Antiphospholipid syndrome Thrombosis
Primary
APS
Secondary
APS
Not
specified Venous Arterial
Venous and
arterial
Small
vessel Not specified
APS
thrombosis
259 164 (63%) 50 (17–87) 150 45 64 160 55 26 4 14
Non-APS
thrombosis
204 116 (57%) 46 (19–85) NA NA NA 149 47 5 0 3
Autoimmune
diseases
196 158 (81%) 46 (16–83) NA NA NA NA NA NA NA NA
Controls 194 170 (88%) 39 (18–82) NA NA NA NA NA NA NA NA
Total
population
853 608 (71%) 46 (16–87) 150 45 64 309 102 31 4 17
APS, antiphospholipid syndrome; NA, not applicable.
Table 2 Triple-positive patients detected with BioPlex 2200, ImmunoCap EliA, ACL AcuStar and QUANTA Lite ELISA in patients with
thrombotic antiphospholipid syndrome (APS), patients with non-APS thrombosis, autoimmune disease (AID) controls and controls
Lupus anticoagulant
positive
Triple-positives
BioPlex 2200 Immuno Cap EliA ACL AcuStar QUANTA Lite ELISA
APS thrombosis (n = 258) 202 118 101 111 89
Non-APS thrombosis (n = 204) 0 0 0 0 0
AID controls (n = 196) 56 22 18 19 14
Controls (n = 193) 16 6 6 4 3
Total patient population (n = 851) 274 146 125 134 106
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discrepant results by the tested solid phase platforms have
a history of thrombosis, illustrating clinical relevance
(Table 4). Median aPL titers were calculated by aCL and
ab2GPI antibody titers above the cut-off. Triple-positives
in agreement across all platforms displayed higher median
aPL titers than triple-positive samples not positive for all
tested platforms (Fig. 1). Statistical difference was
reached for BioPlex2200 (P < 0.001), ACL AcuStar
(P < 0.001) and QUANTA Lite ELISA (P = 0.0029),
but not for ImmunoCapEliA (P = 0.5851), as shown in
Fig. 1.
The sensitivity of triple-positivity for thrombosis was
low compared with LAC alone and varied from 19%
(95% confidence interval [95% CI], 16–23%) up to 26%
(95% CI, 22–30%) between the tested assays (Fig. 2A).
However, higher specificity for thrombosis was obtained,
ranging from 93% (95% CI, 90–95%) up to 96% (95%
CI, 93–97%), as shown in Fig. 2(B). Lupus anticoagulant
positivity resulted in an OR of 3.63 (95% CI, 2.76–4.76).
Triple-positivity was statistically correlated with thrombo-
sis, independent of the solid phase assay used to detect
aCL and ab2GPI IgG/IgM antibodies (Fig. 2B). Odds
ratios for thrombosis ranged from 4.3 (95% CI, 2.7–6.8)
up to 5.2 (95% CI, 3.0–8.9) among the platforms
(Table 5).
Triple-positivity for aCL IgG and ab2GPI IgG or aCL
IgM and ab2GPI IgG IgM was significantly correlated
with thrombosis, independent of the solid phase assay
used. However, positivity for the IgM isotype (aCL IgM
and ab2GPI IgM) was more correlated with thrombosis
than triple-positivity for the IgG isotype (aCL IgG and
ab2GPI IgG) upon aCL and ab2GPI detection by Bio-
Plex 2200, ImmunoCap EliA and ACL AcuStar. On
the other hand, triple-positivity for the IgG isotype was
more strongly correlated with thrombosis than that for
the IgM isotype upon detection of aPL by QUANTA
Lite ELISA. However, the majority of triple-positives
for the IgM isotype were also positive for the IgG isotype
(data not shown). Isolated triple-positivity for the IgG
isotype increased the OR for thrombosis compared with
LAC positivity only in two out of the four tested aPL
solid phase assays (ACL AcuStar and QUANTA Lite
ELISA), as shown in Table 5. In triple-positivity, iso-
lated IgM positivity did not increase OR compared with
LAC. Moreover, isolated triple-positivity for the IgM iso-
type did not reach statistical difference when aPL were
detected with BioPlex 2200 and ACL AcuStar (1.9
[95% CI, 0.6–5.4] and 2.0 [95% CI, 0.7–5.9], respectively).
Positivity for all tested aPL (LAC, aCL IgG, aCL IgM,
ab2GPI IgG and ab2GPI IgM) resulted in the highest
OR for thrombosis, ranging from 8.6 (95% CI, 3.1–24.4)
up to 28.9 (3.9–212.4), detected by BioPlex 2200 and
ACL AcuStar, respectively.
Discussion
Detection of aPL antibodies is accompanied by large
inter-method and inter-laboratory variation [2,4,5,17,18].
Traditionally, aCL and ab2GPI antibodies are detected
by ELISA. Nowadays, more advanced (automated)
systems are available, which are suggested to reduce inter-
laboratory variation [4,17,19–21]. We excluded inter-
laboratory variation by detection of aCL and ab2GPI
antibodies in the same samples at one laboratory (Ghent,
Belgium), carried out by a single technician. Despite
many efforts, standardization of antiphospholipid anti-
body (aPL) assays is far from reached as poor consensus
Table 3 Discrepancies in triple-positivity detection with pairwise
comparison. Number of LAC-positive samples and those positive for
aCL and ab2GPI antibodies (irrespective of the isotype) detected by
BioPlex2200, ImmunoCapEliA, ACL AcuStar and QUANTA
Lite ELISA
BioPlex 2200
ImmunoCap
EliA
ACL
AcuStar
 +  +  +
BioPlex 2200

+
ImmunoCap EliA
 696 30
+ 9 116
ACL AcuStar
 704 13 706 11
+ 1 133 20 114
Quanta Lite ELISA
 701 44 722 23 713 32
+ 4 102 4 102 4 102
Table 4 Discrepancies in triple-positivity detection between BioPlex2200, ImmunoCapEliA, ACL AcuStar and QUANTA Lite ELISA.
Number of triple-positives in (dis)agreement among all four solid phase assays in patients with thrombotic APS, patients with non-APS throm-
bosis, autoimmune disease (AID) controls and controls
BioPlex2200 ImmunoCapEliA
ACL
AcuStar
QUANTA
Lite ELISA
In agreement among all
solid phase assays
APS thrombosis 32 15 25 3 86
AID 10 6 7 2 12
Controls 3 3 1 0 3
Total 45 24 33 5 101
© 2018 International Society on Thrombosis and Haemostasis
Triple-positivity detection is assay dependent 2019
1 000 000
P<0.0001 P<0.0001P = 0.5851 P = 0.0029
1 00 000
10 000
Lo
g 
aP
L 
tit
er
 (A
U)
1000
100
10
Bio
Ple
x®
22
00
Im
mu
no
Ca
p®
Eli
A
AC
L A
cuS
tar
®
QU
AN
TA
 
Lit
e E
LIS
A®
Fig. 1. Antiphospholipid antibody (aPL) titers of triple-positives in (dis)agreement. Log transformed aPL titers in agreement for all platforms
tested are indicated by solid dots; disagreements are indicated by solid squares. Patients without the clinical criteria for the antiphospholipid
syndrome (APS) are indicated in red and patients with a history of thrombosis are indicated in black. Titers are expressed as the median value
of positive aPL titers with interquartile ranges. AU, arbitrary units.
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Fig. 2. Diagnostic efficacy of lupus anticoagulant (LAC) and triple-positive patients detected by BioPlex2200, ImmunoCapEliA, ACL AcuS-
tar and QUANTA Lite ELISA. (A) Sensitivity and (B) specificity for thrombosis (mean  95% confidence interval [95% CI]).
Table 5 Correlation of aPL profiles with thrombosis. Odds ratios (ORs) with 95% confidence intervals (CIs) are shown (significant ORs in
bold)
Positive Negative
BioPlex 2200
(95% CI)
ImmunoCap EliA
(95% CI)
ACL AcuStar
(95% CI)
QUANTA Lite
ELISA (95% CI)
LAC – 3.4 (2.5–4.7) 3.4 (2.5–4.7) 3.4 (2.5–4.7) 3.4 (2.5–4.7)
LAC + aCL + ab2GPI (irrespective
of isotype)
– 4.4 (2.9–6.9) 4.3 (2.7–6.8) 5.0 (3.1–8.1) 5.2 (3.0–8.9)
LAC + aCL IgG + ab2GPI IgG – 4.8 (3.0–7.7) 4.8 (2.8–8.4) 6.0 (3.5–10.2) 6.2 (3.1–12.3)
LAC + aCL IgM + ab2GPI IgM – 5.0 (2.4–10.3) 5.0 (2.4–10.3) 6.7 (2.8–15.9) 4.6 (2.2–9.4)
LAC + aCL IgG + ab2GPI IgG aCL IgM + ab2GPI
IgM
3.4 (2.0–5.8) 3.4 (1.9–6.2) 4.0 (2.3–6.9) 4.8 (2.2–10.3)
LAC + aCL IgM + ab2GPI IgM aCL IgG + ab2GPI
IgG
1.9 (0.6–5.4) 2.7 (1.2–6.5) 2.0 (0.7–5.9) 2.7 (1.2–6.5)
LAC + aCL IgG + ab2GPI IgG + aCL
IgM + ab2GPI IgM
– 8.6 (3.1–24.4) 12.0 (2.8–50.8) 28.9 (3.9–212.4) 10.1 (2.4–43.3)
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is obtained between assays when measuring the same
sample [2,20]. The identification of triple-positive patients
was recently suggested to be less affected by inter-method
variation, thereby better classifying APS patients at risk
[13]. In a retrospective cross-sectional study, the authors
suggested that identification of patients with triple aPL
positivity is platform and method independent, having
compared two methods with a different solid phase from
the same manufacturer [13]. However, they found a dis-
parity of 6 or 9 triple-positives out of 220 patients (121
with APS and 99 with systemic lupus erythematosus),
depending on the cut-off value used, already suggesting
the presence of patients with low levels of ab2GPI and
aCL aPL titers and difficulties in reaching consensus in
the classification of these patients [13,22]. In our cohort,
the highest discrepancy in number of triple-positive sam-
ples was found between BioPlex 2200 and QUANTA
Lite ELISA, with a discrepancy of 29 triple-positives
out of 202 LAC-positive samples (14%). Similar to single
positivity, identification of triple-positives was found to
be assay dependent. In addition, we did not assess the
variation of triple-positivity detection introduced by LAC
assays. Indeed, an external quality control program con-
cluded that inter-method and inter-laboratory variation is
higher in solid phase assays than in LAC detection by
dilute Russell’s Viper Venom Time (dRVVT) assay [3].
However, difficulties still persist in reaching consensus
among weak-positive samples [2–4,23]. The presented
variation in triple-positivity detection may therefore be
underestimated. A possible limitation of our study is that
thrombotic patients under treatment during the time of
blood collection could result in an increased risk of false-
positive LAC tests.
Samples positive for LAC, aCL and ab2GPI antibodies
by one solid phase platform but not by all four tested
platforms have lower median aPL titers, suggesting diffi-
culties in consensus on positivity among low aPL titers
(Fig. 1) [24]. We accept that the cut-off calculated by the
99th percentile of a normal population is the best consen-
sus between sensitivity and specificity, and the clinical rel-
evance of aCL and/or ab2GPI results that are below the
99th percentile needs to be further studied [25]. Few stud-
ies showed that low titers of aCL also were predictive for
thrombotic recurrence [26]. In this study, we transferred
the manufacturer’s cut-off after confirmation, as recom-
mend by the ISTH-SSC guidelines [16]. In terms of clini-
cal practice, a recent questionnaire from the SSC showed
that the majority of laboratories use the same approach,
because only a minority of laboratories have the resources
to calculate a cut-off value from at least 120 normals.
With this cut-off choice applied for all platforms, the
majority of discrepant samples in our study were from
patients that experienced a thrombotic event (Table 4).
A minority of non-thrombotic patients (n = 582,
autoimmune disease and controls) in our study popula-
tion showed triple-positivity (n = 17–28/583 or 2.9–4.8%,
depending on the platform). These should be regarded as
asymptomatic carriers, which is in line with the findings
of Mustonen et al., who found that 5% of asymptomatic
triple-positives were carriers [27].
The association of thrombosis and single aPL positivity
is debated because results are contrary. Recent studies
showed that the risk of thrombotic events increases with
the number of positive tests in APS patients and the cre-
ation of antibody profiles and test combinations increases
the association with thrombosis [7,8,28–30]. On the other
hand, another study showed a strong association between
single aPL positivity and thrombosis in pediatric APS
patients [31]. Although single positivity is not always sig-
nificantly correlated with thrombosis, within the current
guidelines all aPL have the same diagnostic value [1]. In
our cohort, we confirmed the strong correlation between
triple-positivity and thrombosis, as triple-positivity was
significantly correlated with thrombosis independent of
the platform used. A large observational study investi-
gated the incidence of thrombosis in obstetric APS
patients. Frequencies of thrombotic events were assessed
in 517 APS patients, 279 women carrying a genetic throm-
bophilia polymorphism and 796 women with negative
thrombophilia polymorphism results [11]. Computed risks
for thrombosis of LAC positivity and triple-positivity
were globally concordant [11]. However, triple-positivity
was a predictor for pulmonary embolism, whereas LAC
positivity alone was not [11]. In an Italian cohort, 618
patients were referred to aPL testing, of which 55% met
the clinical criteria consistent with the Sapporo criteria
[7]. A statistically significant correlation between LAC
and thrombosis was found (OR, 4.4; 95% CI, 1.5–13.3)
[7]. In triple-positive patients the association with throm-
bosis increased even further (OR, 33.3; 95% CI, 7.0–
157.6), suggesting an additional value of triple-positivity
detection in thrombotic risk stratification [7]. Patient pop-
ulation and aPL detection method may impact the corre-
lation of thrombosis with triple-positivity and the role of
aCL and ab2GPI antibodies in addition to LAC. It has
already been shown that the presence of aCL and ab2GPI
of the same isotype reinforces the clinical probability of
APS [32]. We confirmed that ORs for all platforms are
higher for triple-positivity with concordance of isotype
compared with triple-positivity including combinations of
aCL and ab2GPI irrespective of isotype, except for one
platform (QUANTA Lite ELISA) with lower OR for
IgM triple-positivity compared with the OR for triple-
positivity irrespective of the isotype.
Our results clearly illustrate the wide variation in
thrombotic association introduced by aPL detection
methods. In LAC positives, ‘isolated’ IgM or ‘isolated’
IgG aPL was less correlated with thrombosis than
triple-positivity irrespective of the isotype. Interestingly,
positivity for LAC, aCL and ab2GPI antibodies for both
isotypes resulted in the strongest correlation with throm-
bosis. Therefore, both IgG and IgM antibodies are of
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added value in stratification of risk of thrombosis in
APS. However, IgM did not add any value in thrombotic
association to LAC positives in the absence of IgG aPL.
In conclusion, detection of triple-positivity varied
among commercially available solid phase assays detect-
ing aCL and ab2GPI antibodies. However, triple-positiv-
ity (irrespective of the isotype) was statistically correlated
with thrombosis, independent of the solid phase assay
used. Except for one platform, concordance of isotype
resulted in the highest OR. Detection of IgM antibodies
in triple-positivity was only of added clinical value in
combination with LAC, aCL IgG and ab2GPI IgG pos-
itivity. These data confirm the high association of triple-
positivity with thrombosis and show that the isotype
and solid phase assay used to detect aPL affect the
association with thrombosis. As triple-positive APS
patients have an increased risk of thrombotic recurrence,
standardization in triple-positivity detection is urgently
warranted.
Addendum
K. M. J. Devreese, B. de Laat and H. Kelchtermans
designed the study. K. M. J. Devreese organized the sam-
ple collection at the different centers. K. M. J. Devreese,
D. Wahl, G. W. Moore and J. Musiał collected samples
and identified sample characteristics. Samples were ana-
lyzed under the supervision of K. M. J. Devreese. W.
Chayoua, K. M. J. Devreese, B. de Laat and H. Kelchter-
mans interpreted data, performed statistical analyses and
wrote the manuscript. D. Wahl, G. W. Moore and J.
Musiał critically reviewed the manuscript.
Acknowledgements
The authors thank M. Luypaert for his technical assis-
tance, Bio-Rad Laboratories, ThermoFisher/Phadia, Wer-
fen/Instrumentation Laboratory and Inova Diagnostics for
providing the test kits for the detection of ab2GPI and
aCL IgG and IgM antibodies and S. Zuily, A. Tripodi, P.
Fontana and J. Remijn for providing patient samples.
Disclosure of Conflict of Interests
G. W. Moore reports personal fees from DSM Pen-
tapharm, outside the submitted work, and has been a
member of the Coagulation Advisory Board for Roche
Diagnostics. The other authors state that they have no
conflict of interest.
Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article:
Table S1. Technical specifications of the solid phase
assays. NS, Not specified.
Table S2. Distribution of aCL and ab2GPI antibodies in
LAC positive patients with thrombotic APS.
References
1 Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cer-
vera R, Derksen RHWM, de Groot PG, Koike T, Meroni PL,
Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Kri-
lis SA. International consensus statement on an update of the
classification criteria for definite antiphospholipid syndrome
(APS). J Thromb Haemost 2006; 4: 295–306.
2 Devreese KM. Antiphospholipid antibody testing and standard-
ization. Int J Lab Hematol 2014; 36: 352–63.
3 Favaloro EJ. Variability and diagnostic utility of antiphospho-
lipid antibodies including lupus anticoagulants. Int J Lab Hema-
tol 2013; 35: 269–74.
4 Favaloro EJ, Franchini M, Lippi G. Biological therapies for von
Willebrand disease. Expert Opin Biol Ther 2012; 12: 551–64.
5 Favaloro EJ, McVicker W, Zhang Y, Hamdam S, Huynh M,
Peris P, O’Neal M, Hocker N. Improving the inter-laboratory
harmonization of the international normalized ratio (INR): uti-
lizing the concept of transference to estimate and/or validate
international sensitivity index (ISI) and mean normal prothrom-
bin time (MNPT) values and/or to eliminate measurement bias.
Clin Lab Sci 2012; 25: 13–25.
6 Wong R, Wilson R, Pollock W, Steele R, Gillis D. Anti-cardioli-
pin antibody testing and reporting practices among laboratories
participating in a large external Quality Assurance Program.
Pathology 2004; 36: 174–81.
7 Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Ili-
ceto S. Antibody profiles for the diagnosis of antiphospholipid
syndrome. Thromb Haemost 2005; 93: 1147–52.
8 Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba
N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Paday-
attil Jose S, Iliceto S. Clinical course of high-risk patients diag-
nosed with antiphospholipid syndrome. J Thromb Haemost 2010;
8: 237–42.
9 Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA,
Bertolaccini ML. Clinical accuracy for diagnosis of antiphospho-
lipid syndrome in systemic lupus erythematosus: evaluation of 23
possible combinations of antiphospholipid antibody specificities.
J Thromb Haemost 2012; 10: 2512–8.
10 Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT.
Risk Scale for the diagnosis of antiphospholipid syndrome. Ann
Rheum Dis 2011; 70: 1517–8.
11 Gris JC, Bouvier S, Molinari N, Galanaud JP, Cochery-Nouvel-
lon E, Mercier E, Fabbro-Peray P, Balducchi JP, Mares P, Quere
I, Dauzat M. Comparative incidence of a first thrombotic event
in purely obstetric antiphospholipid syndrome with pregnancy
loss: the NOH-APS observational study. Blood 2012; 119: 2624–
32.
12 Krilis SA, Giannakopoulos B. Laboratory methods to detect
antiphospholipid antibodies. Hematology Am Soc Hematol Educ
Program 2014; 2014: 321–8.
13 Iwaniec T, Kaczor MP, Celinska-Lowenhoff M, Polanski S,
Musial J. Identification of patients with triple antiphospholipid
antibody positivity is platform and method independent. Pol
Arch Med Wewn 2016; 126: 19–24.
14 Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/
IgM antiphospholipid antibodies present in the classification cri-
teria for the antiphospholipid syndrome: a critical review of their
association with thrombosis. J Thromb Haemost 2016; 14: 1530–
48.
© 2018 International Society on Thrombosis and Haemostasis
2022 W. Chayoua et al
15 Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De
Groot PG. Update of the guidelines for lupus anticoagulant
detection. J Thromb Haemost 2009; 7: 1737–40.
16 Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T,
Ortel TL. Testing for antiphospholipid antibodies with solid
phase assays: guidance from the SSC of the ISTH. J Thromb
Haemost 2014; 12: 792–5.
17 Devreese K, Hoylaerts MF. Laboratory diagnosis of the
antiphospholipid syndrome: a plethora of obstacles to overcome.
Eur J Haematol 2009; 83: 1–16.
18 Urbanus RT, de Groot PG. Antiphospholipid antibodies–we are
not quite there yet. Blood Rev 2011; 25: 97–106.
19 Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M,
Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anti-
cardiolipin antibody assay: a methodological analysis for a better
consensus in routine determinations–a cooperative project of the
European Antiphospholipid Forum. Thromb Haemost 2001; 86:
575–83.
20 Favaloro EJ, Wong RC, Jovanovich S, Roberts-Thomson P. A
review of beta2 -glycoprotein-l antibody testing results from a
peer-driven multilaboratory quality assurance program. Am J
Clin Pathol 2007; 127: 441–8.
21 Devreese KM, Poncet A, Lindhoff-Last E, Musial J, de Moer-
loose P, Fontana P. A multicenter study to assess the repro-
ducibility of antiphospholipid antibody results produced by an
automated system. J Thromb Haemost 2017; 15: 91–5.
22 Iwaniec T, Kaczor MP, Celinska-Lowenhoff M, Polanski S,
Musial J. Clinical utility of automated chemiluminescent
antiphospholipid antibody assay. Thromb Res 2015; 136: 1033–9.
23 Reber G, Meijer P. In ECAT veritas? Lupus 2012; 21: 722–4.
24 Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan
E, Facchinetti M, Pengo V. Influence of different IgG
anticardiolipin antibody cut-off values on antiphospholipid syn-
drome classification. J Thromb Haemost 2008; 6: 1693–6.
25 Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on
Lupus Anticoagulant/Antiphospholipid A. Laboratory criteria
for antiphospholipid syndrome: communication from the SSC of
the ISTH. J Thromb Haemost 2018; 16: 809–13.
26 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin anti-
bodies predict early recurrence of thromboembolism and death
among patients with venous thromboembolism following antico-
agulant therapy. Duration of Anticoagulation Study Group. Am
J Med 1998; 104: 332–8.
27 Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent
antiphospholipid antibody (aPL) in asymptomatic carriers as a
risk factor for future thrombotic events: a nationwide prospective
study. Lupus 2014; 23: 1468–76.
28 Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skog-
stad M, Sandset PM. The association of antiphospholipid anti-
bodies with pregnancy-related first time venous thrombosis–a
population-based case-control study. Thromb Res 2010; 125:
e222–7.
29 Devreese KM. Antiphospholipid antibodies: evaluation of the
thrombotic risk. Thromb Res 2012; 130(Suppl. 1): S37–40.
30 Devreese K, Peerlinck K, Hoylaerts MF. Diagnostic test combi-
nations associated with thrombosis in lupus anticoagulant posi-
tive patients. Thromb Haemost 2011; 105: 736–8.
31 Ma J, Song H, Wei M, He Y. Clinical characteristics and throm-
bosis outcomes of paediatric antiphospholipid syndrome: analysis
of 58 patients. Clin Rheumatol 2017; 37: 1295–303.
32 Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A.
What have we learned about antiphospholipid syndrome from
patients and antiphospholipid carrier cohorts? Semin Thromb
Hemost 2012; 38: 322–7.
© 2018 International Society on Thrombosis and Haemostasis
Triple-positivity detection is assay dependent 2023
